• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药代动力学模型的模糊评价。

Fuzzy Evaluation of Pharmacokinetic Models.

机构信息

Instituto Politécnico Nacional, Centro de Investigación y Desarrollo de Tecnología Digital (CITEDI-IPN), Av. Instituto Politécnico Nacional, No. 1310, Col. Nueva Tijuana, 22435 Tijuana, BC, Mexico.

Facultad de Ciencias Químicas e Ingeniería, Universidad Autónoma de Baja California, Calzada Universidad 14418, Parque Industrial Internacional Tijuana, 22390 Tijuana, BC, Mexico.

出版信息

Comput Intell Neurosci. 2018 Nov 1;2018:1983897. doi: 10.1155/2018/1983897. eCollection 2018.

DOI:10.1155/2018/1983897
PMID:30728832
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6341258/
Abstract

Population pharmacokinetic (PopPK) models allow researchers to predict and analyze drug behavior in a population of individuals and to quantify the different sources of variability among these individuals. In the development of PopPK models, the most frequently used method is the nonlinear mixed effect model (NLME). However, once the PopPK model has been developed, it is necessary to determine if the selected model is the best one of the developed models during the population pharmacokinetic study, and this sometimes becomes a multiple criteria decision making (MCDM) problem, and frequently, researchers use statistical evaluation criteria to choose the final PopPK model. The used evaluation criteria mentioned above entail big problems since the selection of the best model becomes susceptible to the human error mainly by misinterpretation of the results. To solve the previous problems, we introduce the development of a software robot that can automate the task of selecting the best PopPK model considering the knowledge of human expertise. The software robot is a fuzzy expert system that provides a method to systematically perform evaluations on a set of candidate PopPK models of commonly used statistical criteria. The presented results strengthen our hypothesis that the software robot can be successfully used to evaluate PopPK models ensuring the selection of the best PopPK model.

摘要

群体药代动力学(PopPK)模型允许研究人员预测和分析个体人群中的药物行为,并量化这些个体之间的不同变异来源。在 PopPK 模型的开发中,最常用的方法是非线性混合效应模型(NLME)。然而,一旦开发了 PopPK 模型,就有必要确定在群体药代动力学研究中,所选模型是否是已开发模型中最好的一个,这有时会成为多准则决策问题(MCDM),并且研究人员经常使用统计评估标准来选择最终的 PopPK 模型。上述使用的评估标准存在很大问题,因为选择最佳模型容易受到人为错误的影响,主要是由于对结果的误解。为了解决上述问题,我们引入了软件机器人的开发,该机器人可以在考虑人类专业知识的情况下,自动选择最佳 PopPK 模型。软件机器人是一个模糊专家系统,它提供了一种方法,可以系统地对一组常用统计标准的候选 PopPK 模型进行评估。所呈现的结果证实了我们的假设,即软件机器人可以成功地用于评估 PopPK 模型,从而确保选择最佳的 PopPK 模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/5299155dab68/CIN2018-1983897.alg.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/512cb52bd70a/CIN2018-1983897.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/349d0740b58d/CIN2018-1983897.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/d8c9b916ec5f/CIN2018-1983897.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/6f7343665e6e/CIN2018-1983897.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/5299155dab68/CIN2018-1983897.alg.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/512cb52bd70a/CIN2018-1983897.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/349d0740b58d/CIN2018-1983897.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/d8c9b916ec5f/CIN2018-1983897.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/6f7343665e6e/CIN2018-1983897.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fef/6341258/5299155dab68/CIN2018-1983897.alg.001.jpg

相似文献

1
Fuzzy Evaluation of Pharmacokinetic Models.药代动力学模型的模糊评价。
Comput Intell Neurosci. 2018 Nov 1;2018:1983897. doi: 10.1155/2018/1983897. eCollection 2018.
2
Fundamentals of population pharmacokinetic modelling: modelling and software.群体药代动力学建模基础:建模与软件。
Clin Pharmacokinet. 2012 Aug 1;51(8):515-25. doi: 10.2165/11634080-000000000-00000.
3
A systematic review of population pharmacokinetic analyses of polyclonal immunoglobulin G therapy.多克隆免疫球蛋白 G 治疗的群体药代动力学分析的系统评价。
Int Immunopharmacol. 2021 Aug;97:107721. doi: 10.1016/j.intimp.2021.107721. Epub 2021 May 4.
4
Parametric Approaches in Population Pharmacokinetics.群体药代动力学中的参数方法。
J Clin Pharmacol. 2022 Feb;62(2):125-141. doi: 10.1002/jcph.1633. Epub 2020 Oct 26.
5
Applications of population pharmacokinetics in current drug labelling.群体药代动力学在当前药品标签中的应用。
J Clin Pharm Ther. 2007 Feb;32(1):57-79. doi: 10.1111/j.1365-2710.2007.00799.x.
6
A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.用于药代动力学和药效学分析的计算机模拟软件之批判
Curr Clin Pharmacol. 2018;13(4):216-235. doi: 10.2174/1574884713666181025144845.
7
Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.CYP2C19、UGT1A8和UGT2B7对癫痫患儿丙戊酸清除率的影响:一项群体药代动力学模型研究
Eur J Clin Pharmacol. 2018 Aug;74(8):1029-1036. doi: 10.1007/s00228-018-2440-6. Epub 2018 Apr 17.
8
Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.使用集成工作流程提高群体药代动力学建模的效率和质量。
J Pharmacokinet Pharmacodyn. 2014 Aug;41(4):319-34. doi: 10.1007/s10928-014-9370-4. Epub 2014 Jul 24.
9
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.HER2酪氨酸激酶抑制剂CP-724,714在晚期恶性HER2阳性实体瘤患者中的群体药代动力学
Cancer Chemother Pharmacol. 2007 Nov;60(6):799-809. doi: 10.1007/s00280-007-0427-6. Epub 2007 Feb 7.
10
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.原发性中枢神经系统淋巴瘤患者大剂量甲氨蝶呤的群体药代动力学。
J Pharm Sci. 2018 May;107(5):1454-1460. doi: 10.1016/j.xphs.2018.01.004. Epub 2018 Jan 10.

引用本文的文献

1
The future of antimicrobial dosing in the ICU: an opportunity for data science.重症监护病房抗菌药物给药的未来:数据科学的机遇。
Intensive Care Med. 2021 Dec;47(12):1481-1483. doi: 10.1007/s00134-021-06549-1. Epub 2021 Oct 11.

本文引用的文献

1
Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.三种不同结构的群体药代动力学模型预测伏立康唑未来浓度的预测性能比较评估
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6806-6812. doi: 10.1128/AAC.00970-16. Print 2016 Nov.
2
A novel Fuzzy Expert System for the identification of severity of carpal tunnel syndrome.一种新型的模糊专家系统,用于识别腕管综合征的严重程度。
Biomed Res Int. 2013;2013:846780. doi: 10.1155/2013/846780. Epub 2013 Sep 3.
3
A review on estimation of stochastic differential equations for pharmacokinetic/pharmacodynamic models.
估算药代动力学/药效动力学模型的随机微分方程综述。
Adv Drug Deliv Rev. 2013 Jun 30;65(7):929-39. doi: 10.1016/j.addr.2013.03.005. Epub 2013 Mar 22.
4
Derivation of various NONMEM estimation methods.各种NONMEM估计方法的推导。
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):575-93. doi: 10.1007/s10928-007-9060-6. Epub 2007 Jul 10.
5
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.用于外部模型评估的指标及其在格列齐特群体药代动力学中的应用。
Pharm Res. 2006 Sep;23(9):2036-49. doi: 10.1007/s11095-006-9067-5. Epub 2006 Aug 12.
6
Prediction discrepancies for the evaluation of nonlinear mixed-effects models.非线性混合效应模型评估中的预测差异。
J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):345-67. doi: 10.1007/s10928-005-0016-4. Epub 2005 Nov 13.
7
Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.非线性混合效应建模——从方法学与软件开发到推动药物研发科学中的应用
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):161-83. doi: 10.1007/s10928-005-0062-y. Epub 2005 Nov 7.
8
Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen.接受每日一次给药方案的住院患者中妥布霉素的群体药代动力学。
Int J Antimicrob Agents. 2000 Aug;15(3):185-91. doi: 10.1016/s0924-8579(00)00172-2.